References
- Hommel E., Parving H‐H., Mathiesen E. R., Edsberg B., Nielsen M. D., Giese J. Effect of captopril on kidney function in insulin‐dependent diabetic patients with nephropathy. Br Med J 1986; 293: 466–70
- Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–62
- Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60
- Brenner B. M., Cooper M. E., de Zeeuw D., Keane W. F., Mitch W. E., Parving H‐H. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9
- Parving H‐H., Lehnert H., Bröchner‐Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8
- Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001; 19: 829–42
- Epstein M., Buckalew V., Martinez F., Altamirano J., Roniker B., Kleiman J., et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002; 15: A24
- Rachmani R., Slavachevsky I., Amit M., Levi Z., Kedar Y., Berla M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471–5
- Sato A., Hayashi K., Naruse M., Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–8
- Davies E., Holloway C. D., Ingram M. C., Inglis G. C., Friel E. C., Morrison C., et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999; 33: 703–7
- Brand E., Chatelain N., Mulatero P., Fery I., Curnow K., Jeunemaitre X., Corvol P., et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32: 198–204
- Kurland L., Melhus H., Karlsson J., Kahan T., Malmqvist K., Ohman P., et al. Aldosterone synthase (CYP11B2) –344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus the Atenolol (SILVHIA) Trial. Am J Hypertens 2002; 15: 389–93
- Andersen S., Tarnow L., Cambien F., Rossing P., Juhl T. R., Deinum J., et al. Long‐term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?. Diabetes Care 2003; 26: 1501–6
- Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H., et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998; 97: 569–75
- Pojoga L., Gautier S., Blanc H., Guyene T. T., Poirier O., Cambien F., et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998; 11: 856–60
- Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003; 18: 1984–92